First Wave BioPharma to Present at the DealFlow MicroCap Conference
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the DealFlow MicroCap Conference, which will be held January 30 – February 1, 2024 at the Caesars Atlantic City Hotel & Casino, in Atlantic City, New Jersey.
Related news for (FWBI)
- First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
- First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
- First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
- First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program